tiprankstipranks
Dyne Therapeutics downgraded to Neutral from Overweight at JPMorgan
PremiumThe FlyDyne Therapeutics downgraded to Neutral from Overweight at JPMorgan
2M ago
Dyne Therapeutics presents data highlighting FORCE platform
Premium
The Fly
Dyne Therapeutics presents data highlighting FORCE platform
2M ago
Dyne Therapeutics management to meet with Piper Sandler
Premium
The Fly
Dyne Therapeutics management to meet with Piper Sandler
3M ago
Stifel views pullback in Dyne Therapeutics shares as buying opportunity
PremiumThe FlyStifel views pullback in Dyne Therapeutics shares as buying opportunity
4M ago
Morning Movers: U.S. Steel drops after VP Harris opposes sale to Nippon
Premium
The Fly
Morning Movers: U.S. Steel drops after VP Harris opposes sale to Nippon
4M ago
Dyne Therapeutics: Executive Shifts and Promising Clinical Trials
Premium
Company Announcements
Dyne Therapeutics: Executive Shifts and Promising Clinical Trials
4M ago
Dyne Therapeutics price target raised to $53 from $43 at Piper Sandler
PremiumThe FlyDyne Therapeutics price target raised to $53 from $43 at Piper Sandler
4M ago
Dyne Therapeutics price target raised to $55 from $48 at H.C. Wainwright
Premium
The Fly
Dyne Therapeutics price target raised to $55 from $48 at H.C. Wainwright
4M ago
Dyne Therapeutics price target raised to $50 from $42 at Chardan
Premium
The Fly
Dyne Therapeutics price target raised to $50 from $42 at Chardan
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100